LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research

LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

Several other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of LB Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday. BMO Capital Markets upped their price target on shares of LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Roth Capital lowered shares of LB Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $37.00 to $35.00 in a research note on Monday, October 5th. Canaccord Genuity Group started coverage on LB Pharmaceuticals in a research report on Friday, October 9th. They set a “buy” rating and a $65.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of LB Pharmaceuticals in a research note on Monday, October 12th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.40.

LB Pharmaceuticals Stock Performance

NASDAQ:LBRX opened at $44.71 on Tuesday. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -9.68 and a beta of 0.82. LB Pharmaceuticals has a 1 year low of $14.40 and a 1 year high of $50.16. The business has a fifty day moving average of $40.42 and a 200-day moving average of $33.27.

LB Pharmaceuticals (NASDAQ:LBRX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.61) by ($0.18). On average, equities research analysts predict that LB Pharmaceuticals will post -6.05 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spruce Street Capital LP increased its stake in LB Pharmaceuticals by 36.9% in the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock valued at $33,645,000 after buying an additional 370,566 shares during the period. Candriam S.C.A. acquired a new position in shares of LB Pharmaceuticals in the third quarter worth $10,949,000. Eversept Partners LP purchased a new stake in shares of LB Pharmaceuticals during the first quarter worth $2,471,000. Janus Henderson Group PLC purchased a new stake in shares of LB Pharmaceuticals during the first quarter worth $1,613,000. Finally, Bank of New York Mellon Corp acquired a new stake in LB Pharmaceuticals during the second quarter valued at $1,784,000.

LB Pharmaceuticals News Roundup

Here’s some of the latest news about LBRX:

• Positive Sentiment: Zacks Research upgraded LBRX from “strong sell” to “hold,” a less bearish assessment that may provide some support to investor sentiment, though it is not a buy recommendation. Zacks Research recommendations
• Positive Sentiment: HC Wainwright, which maintains a “Buy” rating, modestly improved several 2027 forecasts, including its full-year EPS estimate to a loss of $5.44 per share from $5.48. LB Pharmaceuticals analyst coverage
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $5.98 from $5.47 and lowered its Q4 2026 estimate to a loss of $1.70 from $1.49. It also slightly reduced its Q1 2027 estimate, signaling weaker near-term earnings expectations despite the improvements to later 2027 forecasts. LB Pharmaceuticals analyst coverage

LB Pharmaceuticals Company Profile

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.